Latest Breaking News On - F atha us04746l1044 - Page 1 : comparemela.com

Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term. | May 11, 2023

United statesJulie rathbunMark littonAthira pharmaInternational conference on alzheimerAmerican association of neurologySecurities exchangeAthira pharma incDevelopment rd expensesExchange commissionNational institutes of healthClinical development pipeline programsDrug administrationChief executive officerMini mental state examLabel extension